SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 13,025.14 |
| Enterprise Value ($M) | 11,098.14 |
| Book Value ($M) | 10,901.00 |
| Book Value / Share | 28.25 |
| Price / Book | 1.19 |
| NCAV ($M) | 4,858.00 |
| NCAV / Share | 12.59 |
| Price / NCAV | 2.68 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.31 |
| Return on Assets (ROA) | -0.19 |
| Return on Equity (ROE) | -0.26 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.62 |
| Current Ratio | 3.67 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 8,099.00 |
| Assets | 14,142.00 |
| Liabilities | 3,241.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 3,236.00 |
| Operating Income | -3,945.00 |
| Net Income | -3,561.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -3,004.00 |
| Cash from Investing | 1,949.00 |
| Cash from Financing | 56.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Baillie Gifford & Co | 10.10 | -14.82 | |
| 13G/A | Vanguard Group Inc | 10.20 | 15.13 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1,224,386 | 5,874,029 | 20.84 | |
| 2,411,478 | 10,989,461 | 21.94 | |
| 2,418,102 | 11,539,435 | 20.96 | |
| 3,714,930 | 16,418,719 | 22.63 | |
(click for more detail) |
|||
Financial data and stock pages provided by
Fintel.io